Abstract
Abstract
Background
Decisions on funding new healthcare technologies assume that all health improvements are valued equally. However, public reaction to health technology assessment (HTA) decisions suggests there are health attributes that matter deeply to them but are not currently accounted for in the assessment process. We aimed to determine the relative importance of attributes of illness that influence the value placed on alleviating that illness.
Method
We conducted a discrete choice experiment survey that presented general public respondents with 15 funding decisions between hypothetical health conditions. The conditions were defined by five attributes that characterise serious illnesses, plus the health gain from treatment. Respondent preferences were modelled using conditional logistic regression and latent class analysis.
Results
905 members of the UK public completed the survey in November 2017. Respondents generally preferred to provide treatments for conditions with ‘better’ characteristics. The exception was treatment availability, where respondents preferred to provide treatments for conditions where there is no current treatment, and were prepared to accept lower overall health gain to do so. A subgroup of respondents preferred to prioritise ‘worse’ health states.
Conclusion
This study suggests a preference among the UK public for treating an unmet need; however, it does not suggest a preference for prioritising other distressing aspects of health conditions, such as limited life expectancy, or where patients are reliant on care. Our results are not consistent with the features currently prioritised in UK HTA processes, and the preference heterogeneity we identify presents a major challenge for developing broadly acceptable policy.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference62 articles.
1. Gray A, Clarke P, Wolstenholme J, Wordsworth S. Applied methods of cost-effectiveness analysis in health care. Handbooks in health economic evaluation. Oxford: Oxford University Press; 2011.
2. Culyer AJ. The dictionary of health economics. 2nd ed. Cheltenham: Edward Elgar; 2010.
3. Dakin H, Devlin N, Feng Y, Rice N, O’Neill P, Parkin D. The influence of cost-effectiveness and other factors on nice decisions. Health Econ. 2015;24(10):1256–71. https://doi.org/10.1002/hec.3086.
4. National Institute for Health and Care Excellence. Social value judgements: principles for the development of NICE guidance, 2nd edition. 2008. http://www.nice.org.uk/about/who-we-are/our-principles. Accessed 31 July 2021.
5. Rawlins M, Barnett D, Stevens A. Pharmacoeconomics: NICE’s approach to decision-making. Br J Clin Pharmacol. 2010;70(3):346–9. https://doi.org/10.1111/j.1365-2125.2009.03589.x.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献